register

News & Trends - Pharmaceuticals

MSD, Novartis and more unite alongside Gates Foundation in the flight against COVID-19

Health Industry Hub | March 30, 2020 |

Pharma News: A consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic.

The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide. Effects on health systems, economies, and livelihoods are significant, and effective response requires an unprecedented collaboration across government, academia, private sector, and philanthropy.

As co-chair of a consortium of life science companies headquartered across three continents, Vas Narasimhan, CEO of Novartis, said, “We feel a deep shared responsibility to see if there are specific areas where collaboration across the life sciences industry and the Bill & Melinda Gates Foundation can accelerate solutions to this pandemic. In addition to the individual contributions companies are already making, collective action is critical to ensure any promising studies into vaccines, drugs, and diagnostics are quickly scaled to people around the world who are affected by this pandemic.”

HCP engagement during COVID-19. Fill the gap of reduced fieldforce activities. Health Industry Hub combines expertise in delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.

Companies participating in the collaboration include GSK, Pfizer, MSD, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, Johnson & Johnson, Merck KGaA, Novartis, Sanofi, BD and bioMérieux.

Trials of existing drugs, diagnostic tests, compounds, and investigational vaccines have begun around the world to identify interventions to slow or end the pandemic. Products that demonstrate efficacy will require clinical study, scale up of manufacturing, and distribution if proven effective. These are areas that the life sciences industry has extensive experience in managing for products that reach billions of people every day.

Mark Suzman, chief executive officer of the Bill & Melinda Gates Foundation said, “We know that the private sector is where the technical skills from discovery to clinical trials to commercialization know-how sits. We look to harness that knowledge and experience, combine it where possible, to connect with national regulators and the World Health Organization to see if we can help flatten the curve of this pandemic and make sure the results reach everyone around the world, particularly those at highest risk and the poorest.”

Following a conference call with Gates Foundation leadership earlier this month, companies are working to identify concrete actions that will accelerate treatments, vaccines, and diagnostics to the field. As a first step, 15 companies have agreed to share their proprietary libraries of molecular compounds that already have some degree of safety and activity data – with the COVID-19 Therapeutics Accelerator launched by the Gates Foundation, Wellcome, and Mastercard two weeks ago to quickly screen them for potential against COVID-19. Successful hits would move rapidly into in vivo trials in as little as two months.

“This is an encouraging start in a critical area because if any of these compounds are shown to be effective against COVID-19 it dramatically accelerates the path to product approval and scale up,” said Suzman. “While each of the partners will also be pursuing other efforts in partnership with national governments and other partners, it is a great example of why we are optimistic that this unprecedented collaboration will provide a platform for a fundamentally different kind of partnership to help address this global health emergency.”

Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


Digital & Innovation

Reimagining remote care with Australia’s first virtual hospital

Reimagining remote care with Australia’s first virtual hospital

Health Industry Hub | April 24, 2025 |

Australia’s first virtual hospital is taking on a new role as a national testbed for advancing the future of patient-facing […]

More


News & Trends - MedTech & Diagnostics

Health Minister and Opposition face off at the National Press Club

Health Minister and Opposition face off at the National Press Club

Health Industry Hub | April 24, 2025 |

In a blistering showdown at the National Press Club, Federal Health Minister, Mark Butler, and his Opposition counterpart Senator Anne […]

More


News & Trends - Pharmaceuticals

GSK nabs label expansion for RSV vaccine

GSK nabs label expansion for RSV vaccine

Health Industry Hub | April 24, 2025 |

Coinciding with World Immunisation Week (24-30 April), GSK has secured TGA approval for its respiratory syncytial virus (RSV) vaccine, marking […]

More


News & Trends - MedTech & Diagnostics

Low-value imaging linked to high human cost

Low-value imaging linked to high human cost

Health Industry Hub | April 23, 2025 |

Imagining has become a cornerstone of modern medicine, for their ability to detect cancers, guide surgeries, and uncover internal injuries […]

More


This content is copyright protected. Please subscribe to gain access.